← back to search

Claus Neurohr

Robert Bosch Hospital ·
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Transplantation: Methods and Outcomes, Pulmonary Hypertension Research and Treatments, and Respiratory Support and Mechanisms.
h-index
42
citations
5,856
works
178
NIH funding
primary concept
Medicine
email

Recent publications

Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry
ERJ Open Research 2025cited by 4position: middledoi
Community-acquired pneumonia in diabetic patients is characterised by a distinct pathogen spectrum and enhanced inflammation: results from CAPNETZ, a prospective observational cohort study
Infection 2025cited by 1position: middledoi
IL-33 controls IL-22-dependent antibacterial defense by modulating the microbiota
Proceedings of the National Academy of Sciences 2024cited by 11position: middledoi
Estimated annual healthcare costs after acute pulmonary embolism: results from a prospective multicentre cohort study
European Heart Journal - Quality of Care and Clinical Outcomes 2024cited by 8position: middledoi
Maintenance OCS Were Used More Frequently Than Biologics in Patients with Uncontrolled GINA 4/5 Asthma in Germany in 2019
Journal of Asthma and Allergy 2024cited by 6position: middledoi
Health Care Situation in the Treatment of Uncontrolled GINA Step 4/5 Patients in Germany
Journal of Asthma and Allergy 2023cited by 2position: middledoi
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study
European Heart Journal 2022cited by 180position: middledoi
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis
The Journal of Heart and Lung Transplantation 2022cited by 69position: middledoi
Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany
Journal of Asthma and Allergy 2022cited by 34position: middledoi
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
The Lancet Respiratory Medicine 2021cited by 510position: middledoi
Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism
CHEST Journal 2021cited by 63position: middledoi
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
The Journal of Heart and Lung Transplantation 2020cited by 205position: middledoi
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry
European Respiratory Journal 2020cited by 188position: middledoi
Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial
Journal of Clinical Medicine 2020cited by 53position: middledoi
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry
Journal of Clinical Medicine 2020cited by 48position: middledoi
The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry
Respiratory Research 2019cited by 130position: middledoi
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
The Lancet Respiratory Medicine 2019cited by 104position: middledoi
A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation
American Journal of Transplantation 2019cited by 57position: middledoi
Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension
The Journal of Heart and Lung Transplantation 2018cited by 35position: middledoi
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry
Respiratory Research 2017cited by 214position: middledoi
Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study
Journal of Thrombosis and Thrombolysis 2016cited by 64position: middledoi
An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe
European Respiratory Journal 2016cited by 60position: middledoi
Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
Heart 2016cited by 49position: middledoi
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
PLoS ONE 2015cited by 111position: middledoi
S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose
Pneumologie 2013cited by 87position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2017–2024)Dirk Skowasch · University Hospital Bonn5 papers (2017–2024)Hubert Wirtz · Berlin Institute of Health at Charité - Universitätsmedizin Berlin4 papers (2015–2020)Christian Grohé · Saarland University3 papers (2015–2020)Heinrike Wilkens · Universitätsklinikum des Saarlandes3 papers (2017–2020)Michael Kreuter · Johannes Gutenberg University Mainz3 papers (2017–2020)Karl‐Christian Bergmann · Humboldt-Universität zu Berlin3 papers (2022–2024)Marius M. Hoeper · Medizinische Hochschule Hannover3 papers (2015–2018) · 3 papers (2022–2024)David Pittrow · Ludwig-Maximilians-Universität München3 papers (2015–2020)Antje Prasse · Medizinische Hochschule Hannover3 papers (2017–2020)Matthias Held · German Respiratory Society3 papers (2015–2020)Marion Frankenberger · Ludwig-Maximilians-Universität München3 papers (2017–2020)Katrin Milger · Ludwig-Maximilians-Universität München3 papers (2022–2024)Martin Claussen · University Hospital Heidelberg3 papers (2015–2020) · 3 papers (2022–2024) · 3 papers (2022–2024)Ekkehard Grünig · Université Paris-Saclay3 papers (2015–2018) · 3 papers (2022–2024)Martin Schwaiblmair · Charité - Universitätsmedizin Berlin2 papers (2017–2020)